Drugs / KBP-089
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03907202 Comparator | Apr 2018 → Dec 2019 | type 2 diabetes mellitus | KeyBioscience AG | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KBP-089 | “Daily sub-cutaneous injection of KBP-089/Placebo into a lifted skin fold of the abdominal wall.” NCT03907202 ↗ |
| Action | Activate | “a dual activator of both the amylin and calcitonin receptors” NCT03907202 ↗ |
| Route | Subcutaneous | “The IMP is administered by daily subcutaneous injections taken in the morning before breakfast.” NCT03907202 ↗ |